Genetic Diseases, Inborn: Clinical Trials

17,146 trials for Genetic Diseases, Inborn, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9306 completed, 2261 recruiting, 1934 unknown, 1249 terminated. 3736 Phase 2, 3682 Not applicable, 2430 Phase 1, 2133 Phase 3, 805 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 23736Completed 2065, Terminated 466, Recruiting 388, Active not recruiting 263, Unknown 246, Withdrawn 148, Not yet recruiting 111, Enrolling by invitation 36, Suspended 13
Not applicable3682Completed 2028, Unknown 556, Recruiting 443, Not yet recruiting 173, Terminated 170, Active not recruiting 147, Withdrawn 105, Enrolling by invitation 51, Suspended 9
Phase 12430Completed 1420, Recruiting 303, Terminated 238, Active not recruiting 156, Unknown 127, Withdrawn 80, Not yet recruiting 76, Enrolling by invitation 19, Suspended 11
Phase 32133Completed 1286, Terminated 231, Recruiting 180, Active not recruiting 151, Unknown 127, Withdrawn 71, Not yet recruiting 62, Enrolling by invitation 24, Suspended 1
Phase 4805Completed 473, Unknown 94, Terminated 71, Recruiting 70, Withdrawn 37, Not yet recruiting 29, Active not recruiting 28, Enrolling by invitation 3
Early Phase 1180Completed 75, Recruiting 31, Terminated 21, Unknown 21, Active not recruiting 14, Not yet recruiting 10, Withdrawn 6, Enrolling by invitation 2

Follow Genetic Diseases, Inborn: new trials by email Literature Review of Genetic Diseases, Inborn trials Research Report on Genetic Diseases, Inborn

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
Skin Cleanser Combination No.1 - Atopic Dermatitis
Phase 4Not yet recruitingBoston Children's Hospital1002031-01-012026-03-10
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis
Ivermectin Pill - Atopic Dermatitis
Phase 2WithdrawnStanford University2030-12-012024-12-02
Safety and Efficacy of KL003 Cell Injection in Severe Sickle Cell Disease
KL003 Cell Injection - Sickle Cell Disease
Not applicableSuspendedInstitute of Hematology & Blood Diseases Hospital, China32028-03-012026-11-05
Prenatal Transplantation for Fetuses With Fanconi Anemia
IUHSCT for FA-affected fetuses - Fanconi Anemia, Anemia, Hypoplastic, Congenital
Phase 1 / Phase 2Not yet recruitingAgnieszka Czechowicz122028-01-012026-06-16
To Evaluate the Safety and Efficacy of GS1168 Injection in Adult Phenylketonuria
GS1168 injection - Phenylketonuria (PKU)
Early Phase 1Not yet recruitingGritgen Therapeutics Co., Ltd.92027-12-312026-09-10
Self-administered Acupressure in Patients With Sickle Cell Disease
Verum Acupressure (using AcuWand), Sham Acupressure (using AcuWand) - Sickle Cell Disease (SCD)
Not applicableNot yet recruitingUniversity of Cincinnati3002027-10-012026-10-15
Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease
Individuation and Perspective-Taking (IPT), pediatric SCD pain management education session - Sickle Cell Disease, Sickle Cell Anemia in Children
Not applicableNot yet recruitingConnecticut Children's Medical Center302027-09-012026-04-29
Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype
Exa-cel - Sickle Cell Disease
Phase 3WithdrawnVertex Pharmaceuticals Incorporated2027-07-312026-03-25
Epidermal Growth Factor Receptor Inhibition for Keratinopathies
Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma
Phase 1 / Phase 2Not yet recruitingNorthwestern University442027-07-012026-08-03
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
MHB018A injection - Thyroid Eye Disease (TED)
Phase 3Not yet recruitingMinghui Pharmaceutical (Hangzhou) Ltd2192027-07-012026-06-04
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
NTI164, Placebo - RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome
Phase 2 / Phase 3Not yet recruitingFenix Innovation Group402027-07-012026-09-09
Lentiviral Gene Therapy for CGD
Infusion of lentiviral TYF-CGD-modified autologous stem cells - Chronic Granulomatous Disease
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-07-012026-11-02
JULÄINE™ - Neck Skin Laxity Clinical Investigation
Poly-L-Lactic Acid - Neck Skin Laxity
Not applicableNot yet recruitingNordberg Medical AB682027-07-012026-11-16
SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection
Direct intravenous injection of ivlv-X1 lentiviral vector - SCID, X-Linked
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute102027-06-302026-11-03
Lentiviral FIX Gene Therapy
YUVA-GT-F901 - Hemophilia B
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute102027-06-012026-11-02
IT and IV Lentiviral Gene Therapy for X-ALD
Intrathecal and intravenous LV gene therapy - X-linked Adrenoleukodystrophy
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute302027-06-012026-11-02
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD
Lentiviral TYF-ARSA correction of patient's autologous HSCs - Metachromatic Leukodystrophy (MLD)
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-06-012026-11-02
Lentiviral FVIII Gene Therapy
YUVA-GT-F801 - Hemophilia A
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute102027-06-012026-10-30
Prospective Clinical Investigation to Evaluate the Safety and Effectiveness of Juläine™ in Improving Gluteal Skin Laxity in Adults.
Poly-L-Lactic Acid (Juläine™) - Skin Quality, Skin Laxity
Not applicableNot yet recruitingNordberg Medical AB1002027-06-012026-11-16
Direct Lentiviral Injection Gene Therapy for MLD
Intrathecal and intravenous LV gene therapy - Metachromatic Leukodystrophy (MLD)
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-05-312026-11-02

Showing 20 of 17146. Sign in to see all of them.

Narrower conditions

Cystic Fibrosis (1585)  ·  Dermatitis, Atopic (1526)  ·  Anemia, Sickle Cell (1124)  ·  Hemophilia A (791)  ·  Muscular Dystrophy, Duchenne (481)  ·  Down Syndrome (434)  ·  Eczema (332)  ·  Gout (309)  ·  Huntington Disease (292)  ·  Retinitis Pigmentosa (271)  ·  beta-Thalassemia (264)  ·  Hemophilia B (262)  ·  Rare Diseases (248)  ·  Cardiomyopathy, Dilated (244)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (17126)  ·  Nervous System Diseases (5535)  ·  Nutritional and Metabolic Diseases (4681)  ·  Metabolic Diseases (4363)  ·  Skin and Connective Tissue Diseases (3450)  ·  Hemic and Lymphatic Diseases (3417)  ·  Metabolism, Inborn Errors (3291)  ·  Hematologic Diseases (3068)  ·  Pathological Conditions, Signs and Symptoms (2892)  ·  Immune System Diseases (2883)  ·  Skin Diseases (2847)  ·  Central Nervous System Diseases (2781)  ·  Congenital Abnormalities (2641)  ·  Brain Diseases (2557)

Interventions

Blood Specimen Collection (191)  ·  Factor VIII (136)  ·  ivacaftor (109)  ·  Cyclophosphamide (107)  ·  Surveys and Questionnaires (107)  ·  Exercise (96)  ·  Sirolimus (96)  ·  Hydroxyurea (89)  ·  Sodium Chloride (89)  ·  dupilumab (89)  ·  Busulfan (76)  ·  fludarabine (73)  ·  fludarabine phosphate (64)  ·  Saline Solution (63)  ·  Alemtuzumab (62)

Sponsors

Assistance Publique - Hôpitaux de Paris (285)  ·  Pfizer (199)  ·  Novartis Pharmaceuticals (183)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (146)  ·  National Cancer Institute (NCI) (144)  ·  Vertex Pharmaceuticals Incorporated (138)  ·  National Heart, Lung, and Blood Institute (NHLBI) (121)  ·  Hospices Civils de Lyon (117)  ·  Novo Nordisk A/S (114)  ·  Shire (102)  ·  Assiut University (101)  ·  BioMarin Pharmaceutical (100)  ·  Children's Hospital Medical Center, Cincinnati (99)  ·  Massachusetts General Hospital (98)  ·  Sanofi (91)

Countries

United States (7934)  ·  France (2248)  ·  United Kingdom (1888)  ·  Germany (1610)  ·  Canada (1606)  ·  Italy (1448)  ·  Spain (1265)  ·  China (971)  ·  Australia (903)  ·  Netherlands (876)  ·  Belgium (702)  ·  Poland (630)  ·  Turkey (Türkiye) (622)  ·  Japan (528)  ·  Israel (517)

Results publications

PMID 39356039, PMID 37983082, PMID 33331662, PMID 36326435, PMID 31401903, PMID 37975597, PMID 36240296, PMID 39588375, PMID 31215818, PMID 33826132, PMID 40750723, PMID 41385299, PMID 30194931, PMID 33735508, PMID 33825230, PMID 33874971, PMID 37250503, PMID 37254256, PMID 37319354, PMID 39151033, PMID 42162528, PMID 27657681, PMID 32573764, PMID 32671834, PMID 34406619, PMID 36255569, PMID 36463457, PMID 36723913, PMID 37460385, PMID 38775255, PMID 38896380, PMID 40739200, PMID 40993471, PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 19775921, PMID 20236866, PMID 24144944, PMID 25075835, PMID 26196195, PMID 33165005, PMID 34256305, PMID 35061234, PMID 36408587, PMID 36449262, PMID 38489195, PMID 38649657, PMID 39104653

NIH funding

2023 (129), 2018 (116), 2017 (100), 2015 (91), 2016 (86), 2019 (80), 2025 (69), 2014 (68), 2009 (51), 2008 (41), U10CA180886 (28), U54NS065768 (19), 2005 (15), U10CA098543 (15), 2004 (10)